Here are some of the stories Wall Street is watching on Friday, Aug. 22. Stocks and cryptocurrencies surged after Fed Chair ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

According to Bloomberg, the reduction in bonuses will apply to employees who are eligible for short-term incentives in ...

The regulator in its health alert letter mentioned that these stolen drugs are rDNA injectables that require strict ...

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...